Related Experiment Video

Updated: Mar 2, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

40.7K

[Interaction between APOB gene polymorphism and risk factors in coronary heart disease patients without

T Pu1, H Y Yu, M Xu

  • 1Department of Cardiology, Peking University Third Hospital and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, National Health and Family Planning Commission, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100191, China.

Zhonghua Xin Xue Guan Bing Za Zhi
|May 17, 2017
PubMed

Insights

The APOB gene R532W polymorphism is linked to reduced coronary heart disease (CHD) risk in individuals without lipid-lowering treatment. This genetic variation shows interactions with hypertension, smoking, and diabetes, influencing CHD occurrence.

Area of Science:

  • Genetics and Cardiovascular Disease
  • Molecular Biology
  • Population Health

Background:

  • Coronary heart disease (CHD) remains a leading cause of mortality worldwide.
  • Understanding genetic predispositions, such as APOB gene variations, is crucial for risk stratification.
  • The R532W polymorphism in the APOB gene has been investigated for its potential role in CHD susceptibility.

Purpose of the Study:

  • To examine the association between the APOB gene R532W polymorphism and CHD risk in patients not receiving lipid-lowering therapy.
  • To analyze the interaction between the R532W polymorphism and established CHD risk factors.

Main Methods:

  • Case-control study involving 771 CHD patients and 772 controls, all treatment-naïve.
  • Genotyping of the APOB R532W polymorphism using HumanExome BeadChip.
  • Statistical analysis including logistic regression to adjust for confounding factors and interaction analysis.

Main Results:

  • The R532W polymorphism was associated with reduced CHD risk, with A-allele carriers showing approximately 35% lower risk (OR=0.653, P=0.001).
  • Significant interactions were observed: positive additive interactions with hypertension and smoking, and a negative additive interaction with diabetes.
  • Total cholesterol levels were lower in AA genotype individuals compared to GA genotype in controls, but not in CHD patients.

Conclusions:

  • The APOB R532W polymorphism is associated with reduced CHD risk in the absence of lipid-lowering treatment.
  • This genetic variation interacts additively with hypertension and smoking, increasing CHD risk, but interacts negatively with diabetes.
  • Findings suggest potential for targeted genetic risk assessment in populations like the Chinese North Han.

Keywords:
Apolipoproteins BCoronary artery diseasePolymorphism, genetic

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K
Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

15.8K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
523
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
776
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
65